VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020

VASCEPA®, compared with placebo, considerably decreased main composite first and whole MACE (major adverse cardiovascular events) in publish hoc exploratory analyses of sufferers with a historical past of PCI by 34% and 39%,...

Read more
Page 145 of 161 1 144 145 146 161

Welcome Back!

Login to your account below

Create New Account!

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.